Yin Guan

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Improving unified information extraction in Chinese mental health domain with instruction-tuned LLMs and type-verification component.

Improving unified information extraction in Chinese mental health domain with instruction-tuned LLMs and type-verification component.

Journal: Artificial intelligence in medicine

Published: July 06, 2024

Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma.

Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma.

Journal: Cancer biomarkers : section A of Disease markers

Published: December 25, 2023

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma.

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma.

Journal: Frontiers in oncology

Published: August 31, 2022

Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors.

Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors.

Journal: Frontiers in oncology

Published: July 05, 2022

Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.

Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.

Journal: Clinical epidemiology

Published: June 18, 2021

Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS.

Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS.

Journal: Research square

Published: March 10, 2021

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis.

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis.

Journal: Annals of translational medicine

Published: February 11, 2021

Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including >3.32 million people tested with real-time PCR and >219,000 tested positive for SARS-CoV-2 in South Korea, Spain and the United States.

Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including >3.32 million people tested with real-time PCR and >219,000 tested positive for SARS-CoV-2 in South Korea, Spain and the United States.

Journal: medRxiv : the preprint server for health sciences

Published: November 03, 2020

Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.

Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.

Journal: International journal of cancer

Published: February 22, 2020

Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism.

Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism.

Journal: Oncology letters

Published: December 09, 2019

A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study.

A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study.

Journal: The Analyst

Published: August 06, 2019

Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.

Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.

Journal: Journal of Cancer

Published: July 11, 2018

Showing 1-12 of 19

Last Updated: 09/26/2026